Lynch Syndrome Tumor Panel, IHC without interpretation
Use
Assesses the expression status of DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) in tumor tissue via immunohistochemistry to screen for mismatch repair deficiency, suggestive of Lynch syndrome or sporadic MSI‑high tumors.
Special Instructions
Not provided.
Limitations
This test does not include interpretation — results must be interpreted by the ordering physician or pathologist. Loss of expression may be due to somatic or germline causes and additional genetic testing may be needed.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin-fixed, paraffin-embedded tissue block or cell block; or 3 unstained slides (plus 1‑2 additional unstained slides cut at 4 µm)
Other tests from different labs that may be relevant